BIO logo

BIO

Bio-Rad Laboratories, Inc.NYSEHealthcare
$279.99+0.59%OpenMarket Cap: $7.56B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

9.94

PEG

0.07

P/B

1.01

P/S

2.93

EV/EBITDA

10.12

DCF Value

$-208.97

FCF Yield

5.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

51.9%

Operating Margin

8.9%

Net Margin

29.4%

ROE

10.9%

ROA

7.7%

ROIC

1.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$693.2M$720.0M$26.65
FY 2025$2.58B$759.9M$27.87
Q3 2025$653.0M$-341.9M$-12.70
Q2 2025$651.6M$317.8M$11.67

Analyst Ratings

View All
Wells FargoEqual Weight
2025-10-30
CitigroupBuy
2025-10-30
RBC CapitalOutperform
2025-08-01
Wells FargoEqual Weight
2025-08-01
Wells FargoEqual Weight
2025-06-09

Trading Activity

Insider Trades

View All
BARRY JAMESofficer: EVP, President, LSG
SellMon Nov 10
DiVincenzo Jonathan P.officer: President & COO
SellTue Oct 28
DiVincenzo Jonathan P.officer: President & COO
SellTue Oct 28
EVRAN SEDATofficer: EVP, Global Supply Chain
SellTue Oct 21
EVRAN SEDATofficer: EVP, Global Supply Chain
SellTue Oct 21

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NYSE

Beta

1.16

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Peers